The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
The global Enasidenib market was valued at US$ 78 million in 2023 and is anticipated to reach US$ 125.9 million by 2030, witnessing a CAGR of 7.1% during the forecast period 2024-2030.
Enasidenib is a targeted therapy used to treat relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. Its efficacy in inhibiting the mutated IDH2 enzyme and inducing remission has driven market growth. The limited treatment options for this specific subset of AML contribute to its niche status. However, challenges include potential side effects and the need for genetic testing to identify eligible patients. The market competition is relatively small, as Enasidenib remains a targeted therapy for a specific AML subgroup. Despite challenges, the Enasidenib market offers potential for growth as healthcare providers seek effective treatments for patients with IDH2-mutated AML. Continued research and clinical advancements can further drive market expansion.
This report aims to provide a comprehensive presentation of the global market for Enasidenib, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Enasidenib.
Report Scope
The Enasidenib market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Enasidenib market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Enasidenib manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol Myers Squibb
Segment by Type
50mg
100mg
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Enasidenib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Enasidenib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
The global Enasidenib market was valued at US$ 78 million in 2023 and is anticipated to reach US$ 125.9 million by 2030, witnessing a CAGR of 7.1% during the forecast period 2024-2030.
Enasidenib is a targeted therapy used to treat relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. Its efficacy in inhibiting the mutated IDH2 enzyme and inducing remission has driven market growth. The limited treatment options for this specific subset of AML contribute to its niche status. However, challenges include potential side effects and the need for genetic testing to identify eligible patients. The market competition is relatively small, as Enasidenib remains a targeted therapy for a specific AML subgroup. Despite challenges, the Enasidenib market offers potential for growth as healthcare providers seek effective treatments for patients with IDH2-mutated AML. Continued research and clinical advancements can further drive market expansion.
This report aims to provide a comprehensive presentation of the global market for Enasidenib, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Enasidenib.
Report Scope
The Enasidenib market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Enasidenib market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Enasidenib manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol Myers Squibb
Segment by Type
50mg
100mg
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Enasidenib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Enasidenib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Enasidenib Market Overview
1.1 Product Overview and Scope of Enasidenib
1.2 Enasidenib Segment by Type
1.2.1 Global Enasidenib Market Value Comparison by Type (2024-2030)
1.2.2 50mg
1.2.3 100mg
1.3 Enasidenib Segment by Application
1.3.1 Global Enasidenib Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Enasidenib Market Size Estimates and Forecasts
1.4.1 Global Enasidenib Revenue 2019-2030
1.4.2 Global Enasidenib Sales 2019-2030
1.4.3 Global Enasidenib Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Enasidenib Market Competition by Manufacturers
2.1 Global Enasidenib Sales Market Share by Manufacturers (2019-2024)
2.2 Global Enasidenib Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Enasidenib Average Price by Manufacturers (2019-2024)
2.4 Global Enasidenib Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Enasidenib, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Enasidenib, Product Type & Application
2.7 Enasidenib Market Competitive Situation and Trends
2.7.1 Enasidenib Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Enasidenib Players Market Share by Revenue
2.7.3 Global Enasidenib Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Enasidenib Retrospective Market Scenario by Region
3.1 Global Enasidenib Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Enasidenib Global Enasidenib Sales by Region: 2019-2030
3.2.1 Global Enasidenib Sales by Region: 2019-2024
3.2.2 Global Enasidenib Sales by Region: 2025-2030
3.3 Global Enasidenib Global Enasidenib Revenue by Region: 2019-2030
3.3.1 Global Enasidenib Revenue by Region: 2019-2024
3.3.2 Global Enasidenib Revenue by Region: 2025-2030
3.4 North America Enasidenib Market Facts & Figures by Country
3.4.1 North America Enasidenib Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Enasidenib Sales by Country (2019-2030)
3.4.3 North America Enasidenib Revenue by Country (2019-2030)
3.4.4 the United States
3.4.5 Canada
3.5 Europe Enasidenib Market Facts & Figures by Country
3.5.1 Europe Enasidenib Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Enasidenib Sales by Country (2019-2030)
3.5.3 Europe Enasidenib Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Enasidenib Market Facts & Figures by Country
3.6.1 Asia Pacific Enasidenib Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Enasidenib Sales by Country (2019-2030)
3.6.3 Asia Pacific Enasidenib Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Enasidenib Market Facts & Figures by Country
3.7.1 Latin America Enasidenib Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Enasidenib Sales by Country (2019-2030)
3.7.3 Latin America Enasidenib Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Enasidenib Market Facts & Figures by Country
3.8.1 Middle East and Africa Enasidenib Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Enasidenib Sales by Country (2019-2030)
3.8.3 Middle East and Africa Enasidenib Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Enasidenib Sales by Type (2019-2030)
4.1.1 Global Enasidenib Sales by Type (2019-2024)
4.1.2 Global Enasidenib Sales by Type (2025-2030)
4.1.3 Global Enasidenib Sales Market Share by Type (2019-2030)
4.2 Global Enasidenib Revenue by Type (2019-2030)
4.2.1 Global Enasidenib Revenue by Type (2019-2024)
4.2.2 Global Enasidenib Revenue by Type (2025-2030)
4.2.3 Global Enasidenib Revenue Market Share by Type (2019-2030)
4.3 Global Enasidenib Price by Type (2019-2030)
5 Segment by Application
5.1 Global Enasidenib Sales by Application (2019-2030)
5.1.1 Global Enasidenib Sales by Application (2019-2024)
5.1.2 Global Enasidenib Sales by Application (2025-2030)
5.1.3 Global Enasidenib Sales Market Share by Application (2019-2030)
5.2 Global Enasidenib Revenue by Application (2019-2030)
5.2.1 Global Enasidenib Revenue by Application (2019-2024)
5.2.2 Global Enasidenib Revenue by Application (2025-2030)
5.2.3 Global Enasidenib Revenue Market Share by Application (2019-2030)
5.3 Global Enasidenib Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bristol Myers Squibb
6.1.1 Bristol Myers Squibb Corporation Information
6.1.2 Bristol Myers Squibb Description and Business Overview
6.1.3 Bristol Myers Squibb Enasidenib Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bristol Myers Squibb Enasidenib Product Portfolio
6.1.5 Bristol Myers Squibb Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Enasidenib Industry Chain Analysis
7.2 Enasidenib Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Enasidenib Production Mode & Process
7.4 Enasidenib Sales and Marketing
7.4.1 Enasidenib Sales Channels
7.4.2 Enasidenib Distributors
7.5 Enasidenib Customers
8 Enasidenib Market Dynamics
8.1 Enasidenib Industry Trends
8.2 Enasidenib Market Drivers
8.3 Enasidenib Market Challenges
8.4 Enasidenib Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
